Navamedic expands antiperspirant product into German market

Navamedic ASA has signed an exclusive distribution agreement with German pharma company Evolsin Medical to launch its Dermix Absolut Torr antiperspirant product in Germany. The product will be private-labeled for the German market as Evolsin 7-Tage Antitranspirant, with a launch expected early 2026. This collaboration marks Navamedic's entry into Germany, the largest single market for the product launch to date, with 84 million inhabitants.

Dermix Absolut Torr is a cosmetic product developed and manufactured in Sweden, currently available in Nordic countries, the Middle East, and the Balkans. It is also sold under the brand Dermix Absolut Dry. Navamedic chief executive Kathrine Gamborg Andreassen expressed excitement for the collaboration. Evolsin chief executive Daniel Dilges noted the product's fit with their established skin care business.

Navamedic, listed on the Oslo Stock Exchange since 2006, is a Nordic pharmaceutical company focused on prescription, consumer health, and hospital products. Evolsin Medical is a German, family-owned medical skin care business specializing in clinically tested products for chronic skin problems.